Blasi F, Damato S, Cosentini R, Tarsia P, Raccanelli R, Centanni S, Allegra L
Institute of Respiratory Diseases, University of Milan, IRCCS Ospedale Maggiore di Milano, Milan, Italy.
Thorax. 2002 Aug;57(8):672-6. doi: 10.1136/thorax.57.8.672.
A study was undertaken to evaluate Chlamydia pneumoniae chronic infection, other respiratory infections, and functional impairment in patients with chronic bronchitis (stage 1) and to examine chronic C pneumoniae infection, rate of acute exacerbations of chronic bronchitis, and rate of C pneumoniae eradication following antibiotic treatment (stage 2).
In the stage 1 study respiratory specimens from 42 patients with steady state chronic bronchitis were analysed for Gram staining, sputum culture, and C pneumoniae DNA detection by nested touchdown polymerase chain reaction (PCR). On the basis of the results of stage 1, a second population of 141 consecutive patients with steady state mild to moderate chronic bronchitis (FEV(1) >or=50% predicted) was studied. On admission, at regular intervals, and at exacerbation all patients underwent serological testing for C pneumoniae (microimmunofluorescence) and a nested touchdown PCR to detect C pneumoniae DNA was performed on peripheral blood mononuclear cells (PBMCs). Patients were assessed over a 12 month period. Information regarding the previous 12 months was taken from medical records.
Chronic colonisation of the sputum with C pneumoniae was significantly associated with lower FEV(1) and greater airway bacterial colonisation. On admission to the stage 2 study, 80 patients were PCR negative and 61 were PCR positive. Over the 2 years a mean (SD) of 1.43 (1.32) acute exacerbations occurred in PCR negative patients and 2.03 (1.21) in PCR positive patients (p<0.01). During the 12 month follow up period 34 PCR positive patients had acute exacerbations and were treated with azithromycin for 6 weeks. Serological evidence of acute C pneumoniae reinfection/reactivation was found in two of the 34 patients. The rate of C pneumoniae DNA clearance from blood following treatment was 29% at follow up.
Chronic colonisation with C pneumoniae is associated with a higher rate of exacerbations of chronic bronchitis. Long term treatment is required to obtain clearance of the organism from the blood.
开展了一项研究,以评估慢性支气管炎(1期)患者的肺炎衣原体慢性感染、其他呼吸道感染及功能损害,并检查慢性肺炎衣原体感染、慢性支气管炎急性加重率以及抗生素治疗后肺炎衣原体清除率(2期)。
在1期研究中,对42例病情稳定的慢性支气管炎患者的呼吸道标本进行革兰氏染色、痰培养及采用巢式降落聚合酶链反应(PCR)检测肺炎衣原体DNA。基于1期研究结果,对另一组141例病情稳定的轻至中度慢性支气管炎(第1秒用力呼气容积[FEV(1)]≥预计值的50%)患者进行研究。入院时、定期及病情加重时,所有患者均接受肺炎衣原体血清学检测(微量免疫荧光法),并对外周血单个核细胞(PBMC)进行巢式降落PCR以检测肺炎衣原体DNA。对患者进行为期12个月的评估。关于前12个月的信息取自病历。
痰中肺炎衣原体慢性定植与较低的FEV(1)及更严重的气道细菌定植显著相关。在进入2期研究时,80例患者PCR检测为阴性,61例为阳性。在2年期间,PCR阴性患者平均(标准差)发生1.43(1.32)次急性加重,PCR阳性患者为2.03(1.21)次(p<0.01)。在12个月的随访期内,34例PCR阳性患者发生急性加重,并接受阿奇霉素治疗6周。34例患者中有2例发现急性肺炎衣原体再感染/再激活的血清学证据。治疗后随访时血液中肺炎衣原体DNA清除率为29%。
肺炎衣原体慢性定植与慢性支气管炎较高的加重率相关。需要长期治疗以从血液中清除该病原体。